FOI 2024-007

Question 1.  How many patients were treated in the last 4 months (December 2023 to March 2024) by the dermatology department with each of the following products:

·       Abrocitinib - NIL

·       Acitretin - 90 (18+ years old), and 5 (<18 years old)

·       Alitretinoin - 8 (18+ years old), 0 (<18 years old)

·       Azathioprine - We are unable to delineate dermatology patients and so cannot provide an answer for this drug

·       Baricitinib - <5 (18+ years old), and NIL (<18 years old)

·       Ciclosporin - We are unable to delineate dermatology patients and so cannot provide an answer for this drug

·       Dupilumab - 174 (18+ years old), and NIL (<18 years old)

·       Lebrikizumab - NIL

·       Methotrexate - We are unable to delineate dermatology patients and so cannot provide an answer for this drug

·       Mycophenolate mofetil - We are unable to delineate dermatology patients and so cannot provide an answer for this drug

·       Pimecrolimus - 15 (18+ years old), and <5 (<18 years old)

·       Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - for Atopic Dermatitis only - Can only provide most recent data.  Reaudit of this data not yet due.  Data from 2023 audit (not broken down by indication) is 28 patients recorded at RBH over this period and 62 patients recorded at BGH (total = 90 patients)

·       Tacrolimus ointment - 61 (18+ years old), and 13 (<18 years old)

·       Tralokinumab - 12 (18+ years old), and NIL (<18 years old)

·       Upadacitinib - 7 (18+ years old), and NIL (<18 years old)

Question 2.  Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

Age 6 - 11 -

Age 12 - 17 -

Age 18 and above -

The response for question 2 has been incorporated into the response to question 1.